673 related articles for article (PubMed ID: 28865552)
41. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
42. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation.
Barcroft J; Dayoub N; Thong KJ
J Assist Reprod Genet; 2013 Nov; 30(11):1407-13. PubMed ID: 23835721
[TBL] [Abstract][Full Text] [Related]
43. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
44. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
45. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
46. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
47. Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.
Dietrich JE; Freis A; Beedgen F; von Horn K; Holschbach V; Liebscher J; Strowitzki T; Germeyer A
Front Endocrinol (Lausanne); 2020; 11():246. PubMed ID: 32411093
[No Abstract] [Full Text] [Related]
48. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
49. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
50. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization.
Budinetz TH; Mann JS; Griffin DW; Benadiva CA; Nulsen JC; Engmann LL
Fertil Steril; 2014 Sep; 102(3):753-8. PubMed ID: 24954776
[TBL] [Abstract][Full Text] [Related]
51. A matched propensity score study of embryo morphokinetics following gonadotropin-releasing hormone agonist versus human chorionic gonadotropin trigger.
Oron G; Sapir O; Wertheimer A; Shufaro Y; Bar-Gil R; Margalit T; Shlush E; Ben-Haroush A
J Assist Reprod Genet; 2020 Nov; 37(11):2777-2782. PubMed ID: 32980940
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
Meyer L; Murphy LA; Gumer A; Reichman DE; Rosenwaks Z; Cholst IN
Fertil Steril; 2015 Sep; 104(3):637-42. PubMed ID: 26149355
[TBL] [Abstract][Full Text] [Related]
53. Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report.
Cavagna M; Dzik A
Reprod Biomed Online; 2011 Mar; 22(3):317-9. PubMed ID: 21273128
[TBL] [Abstract][Full Text] [Related]
54. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
[TBL] [Abstract][Full Text] [Related]
55. Fertility preservation options in breast cancer patients.
Kasum M; von Wolff M; Franulić D; Čehić E; Klepac-Pulanić T; Orešković S; Juras J
Gynecol Endocrinol; 2015; 31(11):846-51. PubMed ID: 26370157
[TBL] [Abstract][Full Text] [Related]
56. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
57. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
[TBL] [Abstract][Full Text] [Related]
58. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
59. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
60. Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.
O'Neill KE; Senapati S; Dokras A
Fertil Steril; 2015 Jan; 103(1):264-9. PubMed ID: 25450300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
